# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets
DarioHealth (NASDAQ:DRIO) reported quarterly sales of $5.758 million which missed the analyst consensus estimate of $6.758 mill...
Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage ...
Dario selected to provide integrated and proven solutions to improve employee cardiometabolic healthNEW YORK, April 18, 2024 /P...
Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens